Condition: Colorectal Cancer (CRC) · Sponsor: Epiliquid Holding, Inc
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.
This description comes directly from the study's public registry record.
Dr. Victoria Bocanegra, MD, PhD. · +5492616603254 · victoria.bocanegra@epiliquid.com
Dr. Emanuel Campoy, PhD. · +5492615997899 · emanuel.campoy@epiliquid.com
Always discuss trial participation with your own doctor first.
| Epiliquid | Mendoza, Mendoza Province, Argentina | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07168876